CIPLA
Back to Balance Sheet
|
CIPLA Last 5 Year Total Current Liabilities History
[Consolidated]
| Mar2026 | Mar2025 | Mar2024 | Mar2023 | Mar2022 | |
|---|---|---|---|---|---|
| Total Current Liabilities | ₹7,014 Cr | ₹5,484 Cr | ₹5,246 Cr | ₹5,033 Cr | ₹4,913 Cr |
What is the latest Total Current Liabilities ratio of CIPLA ?
| Year | Total Current Liabilities |
|---|---|
| Mar2026 | ₹7,014 Cr |
| Mar2025 | ₹5,484 Cr |
| Mar2024 | ₹5,246 Cr |
| Mar2023 | ₹5,033 Cr |
| Mar2022 | ₹4,913 Cr |
How is Total Current Liabilities of CIPLA Trending?
| Years | Total Current Liabilities | % Change | |
|---|---|---|---|
| Mar2026 | ₹7,014 Cr | 27.89 | |
| Mar2025 | ₹5,484 Cr | 4.54 | |
| Mar2024 | ₹5,246 Cr | 4.22 | |
| Mar2023 | ₹5,033 Cr | 2.45 | |
| Mar2022 | ₹4,913 Cr | - | |
Compare Total Current Liabilities of peers of CIPLA
| Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
| CIPLA | ₹112,475.8 Cr | 2.4% | 2.4% | -12.9% | Stock Analytics | |
| SUN PHARMACEUTICAL INDUSTRIES | ₹425,150.0 Cr | 0.5% | -2.9% | 5% | Stock Analytics | |
| DIVIS LABORATORIES | ₹266,265.0 Cr | 5% | 7.2% | 49.7% | Stock Analytics | |
| TORRENT PHARMACEUTICALS | ₹176,300.0 Cr | -0.5% | -4.5% | 28.9% | Stock Analytics | |
| DR REDDYS LABORATORIES | ₹114,351.0 Cr | 2.7% | 8.4% | 5.1% | Stock Analytics | |
| MANKIND PHARMA | ₹102,315.0 Cr | -1.1% | -1.2% | 3.1% | Stock Analytics | |
CIPLA Share Price vs Sensex
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| CIPLA | 2.4% |
2.4% |
-12.9% |
| SENSEX | 4.5% |
6.1% |
-9.3% |
You may also like the below Video Courses